Swiss National Bank boosted its stake in shares of MEDNAX Inc (NYSE:MD) by 2.3% during the 1st quarter, HoldingsChannel reports. The firm owned 163,000 shares of the company’s stock after buying an additional 3,600 shares during the quarter. Swiss National Bank’s holdings in MEDNAX were worth $9,068,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Delta Capital Management LLC bought a new stake in MEDNAX during the fourth quarter valued at about $227,000. Brown Advisory Inc. bought a new stake in MEDNAX during the fourth quarter valued at about $231,000. Shelton Capital Management bought a new stake in MEDNAX during the fourth quarter valued at about $245,000. Macquarie Group Ltd. raised its holdings in MEDNAX by 36.1% during the fourth quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock valued at $262,000 after acquiring an additional 1,300 shares during the period. Finally, Brandes Investment Partners LP bought a new stake in MEDNAX during the fourth quarter valued at about $324,000. Institutional investors own 97.14% of the company’s stock.
Get MEDNAX alerts:Shares of MEDNAX opened at $46.79 on Friday, according to Marketbeat. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.63. MEDNAX Inc has a 1-year low of $40.56 and a 1-year high of $63.04. The company has a market cap of $4.42 billion, a price-to-earnings ratio of 14.85, a P/E/G ratio of 1.19 and a beta of 0.26.
MEDNAX (NYSE:MD) last issued its quarterly earnings data on Monday, April 30th. The company reported $0.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.07. MEDNAX had a return on equity of 10.13% and a net margin of 9.34%. The company had revenue of $901.90 million for the quarter, compared to analysts’ expectations of $903.75 million. During the same period in the previous year, the firm posted $0.75 earnings per share. The firm’s revenue for the quarter was up 7.9% on a year-over-year basis. analysts predict that MEDNAX Inc will post 3.94 EPS for the current fiscal year.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 22nd. The stock was sold at an average price of $46.43, for a total transaction of $139,290.00. Following the sale, the insider now directly owns 39,716 shares of the company’s stock, valued at $1,844,013.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.
A number of research firms have commented on MD. TheStreet raised MEDNAX from a “c+” rating to a “b” rating in a report on Monday, March 12th. ValuEngine cut MEDNAX from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 2nd. Stephens set a $62.00 target price on MEDNAX and gave the stock a “buy” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. lifted their target price on MEDNAX from $46.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. Finally, Zacks Investment Research cut MEDNAX from a “hold” rating to a “sell” rating in a report on Wednesday, April 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $55.92.
About MEDNAX
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
